Elucidating the Role of C16orf72 in the Cellular Stress Response Network
Project Number5F30CA264513-05
Former Number1F30GM142239-01
Contact PI/Project LeaderAMICI, DAVID RUSSELL
Awardee OrganizationNORTHWESTERN UNIVERSITY AT CHICAGO
Description
Abstract Text
PROJECT SUMMARY
A hallmark of cancer is the ability of malignant cells to maintain viability in the face of stressors such as
aneuploidy, nutrient scarcity, and xenobiotic compounds. This multi-stress-resilience phenotype enables tumor
formation, metastasis, and therapy resistance. Individual molecular pathways co-opted by cancer cells to
promote stress resilience have been thoroughly characterized, but how these specialized pathways are
integrated in complex physiological stress states remains poorly understood. Recently, we used genome-scale
fitness screening data to estimate the intrinsic stress phenotype of 689 diverse cancer cell and identify genes
which are selectively essential in cancer cells highly reliant on multiple distinct stress response pathways.
Through our integrative analysis, we discovered C16orf72, a previously uncharacterized protein which is broadly
stress-inducible and promotes resilience to mechanistically diverse stress insults. We have determined that
C16orf72 physically interacts with HUWE1, an E3 ligase known to ubiquitinate proteins involved in stress
response pathways. Moreover, loss of either C16orf72 or HUWE1 produces highly similar transcriptomic and
ubiquitination phenotypes while not affecting expression of the other factor. Thus, our overarching hypothesis is
that C16orf72 mediates stress resilience by physically interacting with HUWE1 to promote HUWE1-mediated
ubiquitination of proteins with critical roles in diverse stress response pathways. In Aim 1 of this proposal, we will
define the binding interface of C16orf72 and HUWE1 and test several non-exclusive models by which C16orf72
regulates HUWE1 enzymatic activity. In Aim 2, we will determine the substrates and specific modifications which
underly the role of C16orf72 and HUWE1 in cellular stress resilience and canonical stress response signaling.
In Aim 3, we will determine the extent to which C16orf72 is required for in vivo tumorigenesis and the
development of therapy resistance in breast cancer. The long-term goals of the proposed work are to determine
the molecular mechanism by which C16orf72 promotes cellular stress resilience and investigate the therapeutic
potential of blocking the C16orf72/HUWE1 axis in cancer cells.
Public Health Relevance Statement
Project Narrative
Cancer poses a debilitating public health crisis. A hallmark of cancer cells is their ability to grow in the face
of stressors such as aneuploidy, nutrient scarcity, and xenobiotic compounds. The proposed research will
investigate a novel gene, C16orf72, which we recently discovered to be a powerful regulator of stress
resilience in cancer cells and may be a viable target to reduce cancer growth and prevent the development
of therapy resistance.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Amino AcidsAneuploidyBindingBiochemicalBreast Cancer CellBreast Cancer ModelBreast Cancer therapyCancer Cell GrowthCancer cell lineCell LineCell SurvivalCellsCellular StressChemoresistanceCo-ImmunoprecipitationsComplexCyclophosphamideDataDevelopmentDimerizationFellowshipFundingGenesGeneticGoalsGrowthHeat-Shock ResponseHomodimerizationHumanHypoxiaIndividualLysineMalignant Breast NeoplasmMalignant NeoplasmsMapsMeasuresMediatingMessenger RNAModelingModificationMolecularMolecular Sieve ChromatographyMusMutagensNeoplasm MetastasisNutrientOncogenicPathway interactionsPhenocopyPhenotypePhysiologicalProteinsProteomePublic HealthResearchResistanceRoleSeriesStressStress Response SignalingSystemTestingTherapeuticUbiquitinationWorkXenobioticsXenograft procedurebiological adaptation to stresscancer cellcell growth regulationchemotherapyempowermentenvironmental stressorexperimental studyfitnessgenome-widegenotoxicityimprovedin vivomutantnovelpreventprogramspromote resilienceproteotoxicityresponsescreeningstress resiliencestress statestressortherapeutic evaluationtherapy developmenttranscriptomicstumortumor growthtumorigenesisubiquitin-protein ligase
No Sub Projects information available for 5F30CA264513-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30CA264513-05
Patents
No Patents information available for 5F30CA264513-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30CA264513-05
Clinical Studies
No Clinical Studies information available for 5F30CA264513-05
News and More
Related News Releases
No news release information available for 5F30CA264513-05
History
No Historical information available for 5F30CA264513-05
Similar Projects
No Similar Projects information available for 5F30CA264513-05